384
Views
36
CrossRef citations to date
0
Altmetric
Review Article

Do low testosterone levels contribute to ill-health during male ageing?

, &
Pages 168-182 | Received 30 Apr 2012, Accepted 27 Aug 2012, Published online: 24 Oct 2012
 

Abstract

Testosterone regulates male sexual development and body composition. In adult men, testosterone levels exhibit a gradual decline with increasing age. Whether it is age per se or health and behaviour related factors that are responsible for this decline, and the implications thereof for subsequent health remain controversial. Observational studies report associations of lower testosterone levels with poorer health outcomes in ageing men, including frailty, reduced sexual activity, insulin resistance and cardiovascular events and mortality. However, outcome data from randomised clinical trials of testosterone are limited, and are lacking for major endpoints such as cardiovascular events. The risks and benefits of testosterone intervention in older men require further clarification. This article will review the role of testosterone in men, discuss epidemiological and interventional data illuminating its potential role to preserve health during male ageing, consider the limitations of the evidence base and implications for clinical practice, and explore future directions for research in this topical area.

Acknowledgement

This work was supported in part by Award Number R01AG020727 from the National Institute on Aging (A.B.A.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Aging or the National Institutes of Health.

Declaration of interest: B.B.Y. has received speaker’s honoraria and conference support from Bayer and Lilly, research support from Lilly, and is a member of a Lilly Advisory Board. A.B.A. has previously served as a consultant to Lilly USA, LLC (Indianapolis, IN). G.A.W. has received research support and speaking fees from Bayer, research support from Lilly, and is a member of a Lilly Advisory Board. None of these parties had any input into the writing of this manuscript, and no writing or editorial assistance was received.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.